International Journal of Medical Science and Pharmaceutical Research

Loss of motor, sensory, and autonomic abilities is a serious neurological disorder known as spinal cord injury (SCI), which frequently results in permanent disability and a substantial economical burden. Secondary damage processes, including neuroinflammation, are crucial in determining disease progression and functional consequences after the original mechanical trauma. Interleukin-6 (IL-6), a pleiotropic cytokine of the gp130 family, has become one of the main mediators of this process and a critical regulator of inflammatory responses following injury. After SCI, the blood-spinal cord barrier (BSCB) is disrupted, allowing peripheral immune cells such as neutrophils, monocytes/macrophages, and lymphocytes to infiltrate while local microglia and astrocytes are quickly activated. Alongside this intricate cellular interaction is a dynamic cytokine milieu where IL-6 signaling plays a role in both harmful and healing processes. IL-6 exacerbates neuronal loss and demyelination by promoting astrocyte reactivity, glial scar formation, and persistent neuroinflammation through activation of the JAK/STAT3 pathway. Simultaneously, IL-6 signaling integrates inflammatory, apoptotic, and survival signals by interacting with important molecular pathways as NF-κB, MAPK, and PI3K/Akt. According to recent research, the post-SCI microenvironment is shaped by oxidative stress regulators like Nrf2 and new types of inflammatory cell death including PANoptosis. Furthermore, the temporal and context-dependent character of inflammation highlights a dual role: whereas later immune regulation may aid in debris removal and tissue healing, early pro-inflammatory responses contribute to tissue damage. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs), biomaterial-based therapies, antioxidants, and therapeutic methods that target IL-6 signaling have demonstrated promise in reducing neuroinflammation and promoting regeneration. In summary, IL-6 is a crucial node in the intricate neuroimmune network of SCI, connecting cellular death pathways, inflammatory signals, and regeneration processes. In order to design targeted and temporally optimized therapeutic approaches for spinal cord injury, a greater comprehension of IL-6-mediated signaling dynamics may offer new insights.

Spinal Cord Injury (SCI); Interleukin-6 (IL-6); Neuroinflammation; JAK/STAT Signaling Pathway; Glial Scar Formation; Secondary Injury; Microglia Activation; Astrocyte Reactivity; Blood-Spinal Cord Barrier (BSCB); Oxidative Stress; Nrf2 Pathway; PANoptosis; Cytokine Signaling; Immune Cell Infiltration; Neuroregeneration

1. Liu Y, Yang X, He Z, Li J, Li Y, Wu Y, et al. Spinal cord injury: global burden from 1990 to 2019 and projections up to 2030 using Bayesian age-period-cohort analysis. 
2. Wang Y. Global, regional, and national burdens of traumatic brain injury, spinal cord injury, and skull fracture and their attributable risk factors from 1990 to 2021: a systematic analysis of the global burden of disease study 2021. Front Public Health. 2025 Aug 20;13:1622693. 
3. Shen Y, Cao X, Lu M, Gu H, Li M, Posner DA. Current treatments after spinal cord injury: Cell engineering, tissue engineering, and combined therapies. Smart Med. 2022 Dec 26;1:e20220017. Patient Profiles, Health-Related Quality of Life and Support Services in China: Implications for Healthcare and Rehabilitation.
4. Qin H, Diao Y, Hao M, Wang Z, Xie M, Hu X, Zhu T. Analysis and comparison of the trends in burden of spinal cord injury in China and worldwide from 1990 to 2021: an analysis of the global burden of disease study 2021. Front Public Health. 2025 Jan 7;12:1517871. 
5. Gao F, Liu W, Deng C, Wang Z, Wang B, Deng H, Liu Y, Sun L. The Global Macroeconomic Burden of Spinal Cord Injury: A Dynamic Modeling Study from 2020 to 2050. Neuroepidemiology. 2026 Jan 13:1-10. 
6. Kim SH, Kim O, Bae YH, Choi DI, Heo JE, Song WK, Lee BS. Caregiver burden according to ageing and type of care activity in caregivers of individuals with spinal cord injury. Spinal Cord Ser Cases. 2023 Apr 18;9:16.
7. Wu YY, Gao YM, Feng T, Rao JS, Zhao C. Enhancing Functional Recovery After Spinal Cord Injury Through Neuroplasticity: A Comprehensive Review. Int J Mol Sci. 2025 Jul 9;26:6596. 
8. Malekzadeh H, Golpayegani M, Ghodsi Z, Sadeghi-Naini M, Asgardoon M, Baigi V, et al. Direct Cost of Illness for Spinal Cord Injury: A Systematic Review. Global Spine J. 2022 Jul;12:1267-1281.
9. Pan H, Ding M, Zhu L, Sun X, Liu R, Ai S, et al. A national cross-sectional survey on community spinal cord injury individuals profiles, health-related quality of life and support services in China: implications for healthcare and rehabilitation. BMC Musculoskelet Disord. 2024 Oct 1;25:761.
10. Feng T, Hu J, Xie M, Shi G, Wang Q, Yao J, Liu X. Identification and experimental validation of BMX as a crucial PANoptosis‑related gene for immune response in Spinal Cord Injury. PLoS One. 2025 Jul 15;20:e0328002.
11. Covache-Busuioc RA, Toader C, Rădoi MP, Șerban M. Precision Recovery After Spinal Cord Injury: Integrating CRISPR Technologies, AI-Driven Therapeutics, Single-Cell Omics, and System Neuroregeneration. Int J Mol Sci. 2025 Jul 20;26:6966.
12. Zhang C, Li Y, Yu Y, Li Z, Xu X, Talifu Z, et al. Impact of inflammation and Treg cell regulation on neuropathic pain in spinal cord injury: mechanisms and therapeutic prospects. Front Immunol. 2024 Jan 29;15:1334828.
13. Demirezen A, Erbaş O. Balancing Act: NRF2's contradictory roles in cancer progression and therapy. D J Med Sci 2024;10:123-128.
14. Du R, Li Y, Wang GG, Lin W. The clinical application potential of miR-1287-5p in spinal cord injury resulting from spinal trauma and its involvement in modulating the inflammatory response. J Orthop Surg Res. 2025 Sep 26;20(1):852. doi: 10.1186/s13018-025-06240-x
15. Ma T, Wu J, Mu J, Gao J. Biomaterials reinforced MSCs transplantation for spinal cord injury repair. Asian J Pharm Sci. 2022 Jan;17(1):4-19. doi: 10.1016/j.ajps.2021.03.003. Epub 2021 Apr 20.
16. Nowacka A, Śniegocki M, Ziółkowska E. A Review of the Potential Use of Antioxidants in Spinal Cord Injuries. Antioxidants (Basel). 2025 Sep 3;14(9):1081. doi: 10.3390/antiox14091081.
17. Pagan-Rivera LH, Ocasio-Rivera SE, Godoy-Vitorino F, Miranda JD. Spinal cord injury: pathophysiology, possible treatments and the role of the gut microbiota. Front Microbiol. 2024 Dec 18;15:1490855. doi: 10.3389/fmicb.2024.1490855.
18. Gong L, Lv Y, Li S, Feng T, Zhou Y, Sun Y, Mi D. Changes in transcriptome profiling during the acute/subacute phases of contusional spinal cord injury in rats. Ann Transl Med. 2020 Dec;8(24):1682. doi: 10.21037/atm-20-6519.
19. Santos, G. G. dos, Delay, L., Yaksh, T. L., & Corr, M. (2020). Neuraxial Cytokines in Pain States. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.03061
20. Zhou, Y., Liu, Z., Liu, Z., Chen, S., Li, M., Shahveranov, A., Ye, D., & Tian, Y. (2016). Interleukin-6: an emerging regulator of pathological pain. Journal of Neuroinflammation, 13(1). https://doi.org/10.1186/s12974-016-0607-6
21. Akhmetzyanova, E. R., Kletenkov, K., Mukhamedshina, Y., & Rizvanov, A. A. (2019). Different Approaches to Modulation of Microglia Phenotypes After Spinal Cord Injury. Frontiers in Systems Neuroscience, 13. https://doi.org/10.3389/fnsys.2019.00037
22. Zavvarian, M.-M., Modi, A. D., Sadat, S., Hong, J., & Fehlings, M. G. (2024). Translational Relevance of Secondary Intracellular Signaling Cascades Following Traumatic Spinal Cord Injury. International Journal of Molecular Sciences, 25(11), 5708. https://doi.org/10.3390/ijms25115708
23. Li, J., Shui, X., Sun, R., Wan, L., Zhang, B., Xiao, B., & Luo, Z. (2021). Microglial Phenotypic Transition: Signaling Pathways and Influencing Modulators Involved in Regulation in Central Nervous System Diseases. Frontiers in Cellular Neuroscience, 15. https://doi.org/10.3389/fncel.2021.736310
24. Агеева, Т. С., Rizvanov, A. A., & Mukhamedshina, Y. (2024). NF-κB and JAK/STAT Signaling Pathways as Crucial Regulators of Neuroinflammation and Astrocyte Modulation in Spinal Cord Injury. Cells, 13(7), 581. https://doi.org/10.3390/cells13070581
25. Antar, S. A., Mahmoud, A. M., Abdo, W., Gad, C., & Al‐Karmalawy, A. A. (2023). A Comprehensive Overview of Organ Inflammatory Responses: Genesis, Possible Mechanisms, and Mediators of Inflammation. Pharmaceutical Sciences, 29(4), 397–416. https://doi.org/10.34172/ps.2023.9
26. Popiołek-Barczyk, K., & Mika, J. (2016). Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain. Current Medicinal Chemistry, 23(26), 2908–2928. https://doi.org/10.2174/0929867323666160607120124
27. Tan, F., Cao, B.-Q., Zhan, J., & Lai, P.-H. (2021). Mechanism underlying treatment of ischemic stroke using acupuncture: transmission and regulation. Neural Regeneration Research, 16(5), 944. https://doi.org/10.4103/1673-5374.297061
28. Kumar, R., Sporn, K., Kaur, H., Khanna, A., Paladugu, P., Zaman, N., & Tavakkoli, A. (2025). Current Mechanobiological Pathways and Therapies Driving Spinal Health. Bioengineering, 12(8), 886. https://doi.org/10.3390/bioengineering12080886